1
|
Lin Y, Gahn J, Banerjee K, Dobreva G, Singhal M, Dubrac A, Ola R. Role of endothelial PDGFB in arterio-venous malformations pathogenesis. Angiogenesis 2024; 27:193-209. [PMID: 38070064 PMCID: PMC11021264 DOI: 10.1007/s10456-023-09900-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Accepted: 11/05/2023] [Indexed: 04/17/2024]
Abstract
Arterial-venous malformations (AVMs) are direct connections between arteries and veins without an intervening capillary bed. Either familial inherited or sporadically occurring, localized pericytes (PCs) drop is among the AVMs' hallmarks. Whether impaired PC coverage triggers AVMs or it is a secondary event is unclear. Here we evaluated the role of the master regulator of PC recruitment, Platelet derived growth factor B (PDGFB) in AVM pathogenesis. Using tamoxifen-inducible deletion of Pdgfb in endothelial cells (ECs), we show that disruption of EC Pdgfb-mediated PC recruitment and maintenance leads to capillary enlargement and organotypic AVM-like structures. These vascular lesions contain non-proliferative hyperplastic, hypertrophic and miss-oriented capillary ECs with an altered capillary EC fate identity. Mechanistically, we propose that PDGFB maintains capillary EC size and caliber to limit hemodynamic changes, thus restricting expression of Krüppel like factor 4 and activation of Bone morphogenic protein, Transforming growth factor β and NOTCH signaling in ECs. Furthermore, our study emphasizes that inducing or activating PDGFB signaling may be a viable therapeutic approach for treating vascular malformations.
Collapse
Affiliation(s)
- Yanzhu Lin
- Experimental Pharmacology Mannheim (EPM), European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Johannes Gahn
- Experimental Pharmacology Mannheim (EPM), European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Kuheli Banerjee
- Experimental Pharmacology Mannheim (EPM), European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Gergana Dobreva
- Department of Cardiovascular Genomics and Epigenomics, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
- German Centre for Cardiovascular Research (DZHK), Heidelberg, Germany
| | - Mahak Singhal
- Laboratory of AngioRhythms, European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany
| | - Alexandre Dubrac
- Centre de Recherche, CHU St. Justine, Montreal, QC, H3T 1C5, Canada
- Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montreal, QC, H3T 1J4, Canada
| | - Roxana Ola
- Experimental Pharmacology Mannheim (EPM), European Center for Angioscience (ECAS), Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany.
| |
Collapse
|
2
|
Frias-Anaya E, Gallego-Gutierrez H, Gongol B, Weinsheimer S, Lai CC, Orecchioni M, Sriram A, Bui CM, Nelsen B, Hale P, Pham A, Shenkar R, DeBiasse D, Lightle R, Girard R, Li Y, Srinath A, Daneman R, Nudleman E, Sun H, Guma M, Dubrac A, Mesarwi O, Ley K, Kim H, Awad IA, Ginsberg MH, Lopez-Ramirez MA. Mild Hypoxia Accelerates Cerebral Cavernous Malformation Disease Through CX3CR1-CX3CL1 Signaling. Arterioscler Thromb Vasc Biol 2024. [PMID: 38660801 DOI: 10.1161/atvbaha.123.320367] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/01/2023] [Accepted: 04/05/2024] [Indexed: 04/26/2024]
Abstract
BACKGROUND Heterogeneity in the severity of cerebral cavernous malformations (CCMs) disease, including brain bleedings and thrombosis that cause neurological disabilities in patients, suggests that environmental, genetic, or biological factors act as disease modifiers. Still, the underlying mechanisms are not entirely understood. Here, we report that mild hypoxia accelerates CCM disease by promoting angiogenesis, neuroinflammation, and vascular thrombosis in the brains of CCM mouse models. METHODS We used genetic studies, RNA sequencing, spatial transcriptome, micro-computed tomography, fluorescence-activated cell sorting, multiplex immunofluorescence, coculture studies, and imaging techniques to reveal that sustained mild hypoxia via the CX3CR1-CX3CL1 signaling pathway influences cell-specific neuroinflammatory interactions, contributing to heterogeneity in CCM severity. RESULTS Histological and expression profiles of CCM neurovascular lesions (Slco1c1-iCreERT2;Pdcd10fl/fl; Pdcd10BECKO) in male and female mice found that sustained mild hypoxia (12% O2, 7 days) accelerates CCM disease. Our findings indicate that a small reduction in oxygen levels can significantly increase angiogenesis, neuroinflammation, and thrombosis in CCM disease by enhancing the interactions between endothelium, astrocytes, and immune cells. Our study indicates that the interactions between CX3CR1 and CX3CL1 are crucial in the maturation of CCM lesions and propensity to CCM immunothrombosis. In particular, this pathway regulates the recruitment and activation of microglia and other immune cells in CCM lesions, which leads to lesion growth and thrombosis. We found that human CX3CR1 variants are linked to lower lesion burden in familial CCMs, proving it is a genetic modifier in human disease and a potential marker for aggressiveness. Moreover, monoclonal blocking antibody against CX3CL1 or reducing 1 copy of the Cx3cr1 gene significantly reduces hypoxia-induced CCM immunothrombosis. CONCLUSIONS Our study reveals that interactions between CX3CR1 and CX3CL1 can modify CCM neuropathology when lesions are accelerated by environmental hypoxia. Moreover, a hypoxic environment or hypoxia signaling caused by CCM disease influences the balance between neuroinflammation and neuroprotection mediated by CX3CR1-CX3CL1 signaling. These results establish CX3CR1 as a genetic marker for patient stratification and a potential predictor of CCM aggressiveness.
Collapse
Affiliation(s)
- Eduardo Frias-Anaya
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Helios Gallego-Gutierrez
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Brendan Gongol
- Department of Health Sciences, Victor Valley College, Victorville, CA (B.G.)
- Institute for Integrative Genome Biology, 1207F Genomics Building, University of California, Riverside (B.G.)
| | - Shantel Weinsheimer
- Department of Anesthesia and Perioperative Care, Institute for Human Genetics, University of California, San Francisco (S.W., A.S., H.K.)
| | - Catherine Chinhchu Lai
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Marco Orecchioni
- Division of Inflammation Biology, La Jolla Institute for Immunology, CA (M.O., K.L.)
| | - Aditya Sriram
- Department of Anesthesia and Perioperative Care, Institute for Human Genetics, University of California, San Francisco (S.W., A.S., H.K.)
| | - Cassandra M Bui
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Bliss Nelsen
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Preston Hale
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Angela Pham
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Robert Shenkar
- Neurovascular Surgery Program, Department of Neurological Surgery, The University of Chicago Medicine and Biological Sciences, IL (R.S., D.D., R.L., R.G., Y.L., A.S., I.A.A.)
| | - Dorothy DeBiasse
- Neurovascular Surgery Program, Department of Neurological Surgery, The University of Chicago Medicine and Biological Sciences, IL (R.S., D.D., R.L., R.G., Y.L., A.S., I.A.A.)
| | - Rhonda Lightle
- Neurovascular Surgery Program, Department of Neurological Surgery, The University of Chicago Medicine and Biological Sciences, IL (R.S., D.D., R.L., R.G., Y.L., A.S., I.A.A.)
| | - Romuald Girard
- Neurovascular Surgery Program, Department of Neurological Surgery, The University of Chicago Medicine and Biological Sciences, IL (R.S., D.D., R.L., R.G., Y.L., A.S., I.A.A.)
| | - Ying Li
- Neurovascular Surgery Program, Department of Neurological Surgery, The University of Chicago Medicine and Biological Sciences, IL (R.S., D.D., R.L., R.G., Y.L., A.S., I.A.A.)
| | - Abhinav Srinath
- Neurovascular Surgery Program, Department of Neurological Surgery, The University of Chicago Medicine and Biological Sciences, IL (R.S., D.D., R.L., R.G., Y.L., A.S., I.A.A.)
| | - Richard Daneman
- Department of Pharmacology, University of California San Diego, La Jolla. (R.D., M.A.L.-R.)
| | - Eric Nudleman
- Department of Ophthalmology, University of California San Diego, La Jolla. (E.N.)
| | - Hao Sun
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Monica Guma
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Alexandre Dubrac
- Centre de Recherche, CHU St. Justine, Montréal, Quebec, Canada. Département de Pathologie et Biologie Cellulaire, Université de Montréal, Quebec, Canada (A.D.)
| | - Omar Mesarwi
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Klaus Ley
- Division of Inflammation Biology, La Jolla Institute for Immunology, CA (M.O., K.L.)
| | - Helen Kim
- Department of Anesthesia and Perioperative Care, Institute for Human Genetics, University of California, San Francisco (S.W., A.S., H.K.)
| | - Issam A Awad
- Neurovascular Surgery Program, Department of Neurological Surgery, The University of Chicago Medicine and Biological Sciences, IL (R.S., D.D., R.L., R.G., Y.L., A.S., I.A.A.)
| | - Mark H Ginsberg
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
| | - Miguel Alejandro Lopez-Ramirez
- Department of Medicine, University of California San Diego, La Jolla. (E.F.-A., H.G.-G., C.C.L., C.M.B., B.N., P.H., A.P., H.S., M.G., O.M., M.H.G., M.A.L.-R.)
- Department of Pharmacology, University of California San Diego, La Jolla. (R.D., M.A.L.-R.)
| |
Collapse
|
3
|
Künzel SE, Pompös IM, Flesch LTM, Frentzel DP, Knecht VA, Winkler S, Skosyrski S, Rübsam A, Dreher F, Kociok N, Schütte M, Dubrac A, Lange B, Yaspo ML, Lehrach H, Strauß O, Joussen AM, Zeitz O. Exploring the Impact of Saccharin on Neovascular Age-Related Macular Degeneration: A Comprehensive Study in Patients and Mice. Invest Ophthalmol Vis Sci 2024; 65:5. [PMID: 38558091 PMCID: PMC10996979 DOI: 10.1167/iovs.65.4.5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/17/2023] [Accepted: 02/11/2024] [Indexed: 04/04/2024] Open
Abstract
Purpose We aimed to determine the impact of artificial sweeteners (AS), especially saccharin, on the progression and treatment efficacy of patients with neovascular age-related macular degeneration (nAMD) under anti-vascular endothelial growth factor (anti-VEGF-A) treatment. Methods In a cross-sectional study involving 46 patients with nAMD undergoing intravitreal anti-VEGF therapy, 6 AS metabolites were detected in peripheral blood using liquid chromatography - tandem mass spectrometry (LC-MS/MS). Disease features were statistically tested against these metabolite levels. Additionally, a murine choroidal neovascularization (CNV) model, induced by laser, was used to evaluate the effects of orally administered saccharin, assessing both imaging outcomes and gene expression patterns. Polymerase chain reaction (PCR) methods were used to evaluate functional expression of sweet taste receptors in a retinal pigment epithelium (RPE) cell line. Results Saccharin levels in blood were significantly higher in patients with well-controlled CNV activity (P = 0.004) and those without subretinal hyper-reflective material (P = 0.015). In the murine model, saccharin-treated mice exhibited fewer leaking laser scars, lesser occurrence of bleeding, smaller fibrotic areas (P < 0.05), and a 40% decrease in mononuclear phagocyte accumulation (P = 0.06). Gene analysis indicated downregulation of inflammatory and VEGFR-1 response genes in the treated animals. Human RPE cells expressed taste receptor type 1 member 3 (TAS1R3) mRNA and reacted to saccharin stimulation with changes in mRNA expression. Conclusions Saccharin appears to play a protective role in patients with nAMD undergoing intravitreal anti-VEGF treatment, aiding in better pathological lesion control and scar reduction. The murine study supports this observation, proposing saccharin's potential in mitigating pathological VEGFR-1-induced immune responses potentially via the RPE sensing saccharin in the blood stream.
Collapse
Affiliation(s)
- Steffen E. Künzel
- Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Ophthalmology, Hindenburgdamm 30, Berlin, Germany
| | - Inga-Marie Pompös
- Experimental Ophthalmology, Department of Ophthalmology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-University, Berlin, Germany
| | - Leonie T. M. Flesch
- Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Ophthalmology, Hindenburgdamm 30, Berlin, Germany
| | - Dominik P. Frentzel
- Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Ophthalmology, Hindenburgdamm 30, Berlin, Germany
| | - Vitus A. Knecht
- Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Ophthalmology, Hindenburgdamm 30, Berlin, Germany
| | - Silvia Winkler
- Experimental Ophthalmology, Department of Ophthalmology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-University, Berlin, Germany
| | - Sergej Skosyrski
- Experimental Ophthalmology, Department of Ophthalmology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-University, Berlin, Germany
| | - Anne Rübsam
- Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Ophthalmology, Hindenburgdamm 30, Berlin, Germany
| | - Felix Dreher
- Alacris Theranostics, Max-Planck-Straße 3, Berlin, Germany
| | - Norbert Kociok
- Experimental Ophthalmology, Department of Ophthalmology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-University, Berlin, Germany
| | - Moritz Schütte
- Alacris Theranostics, Max-Planck-Straße 3, Berlin, Germany
| | - Alexandre Dubrac
- Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, Quebec, Canada
| | - Bodo Lange
- Alacris Theranostics, Max-Planck-Straße 3, Berlin, Germany
| | - Marie-Laure Yaspo
- Max-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, Berlin, Germany
| | - Hans Lehrach
- Max-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, Berlin, Germany
| | - Olaf Strauß
- Experimental Ophthalmology, Department of Ophthalmology, Charité–Universitätsmedizin Berlin, Corporate Member of Freie Universität, Berlin Institute of Health, Humboldt-University, Berlin, Germany
| | - Antonia M. Joussen
- Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Ophthalmology, Hindenburgdamm 30, Berlin, Germany
| | - Oliver Zeitz
- Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt–Universität zu Berlin, Department of Ophthalmology, Hindenburgdamm 30, Berlin, Germany
| |
Collapse
|
4
|
Gu X, Chen X, Zhang X, Liu K, Li JJ, Lv W, Zeng L, Wu M, Zhou W, Wang W, Shi S, Deng Y, Li Y, Gao X, Ju R, Dubrac A, Liu X, Zhang F. Macrophage-induced integrin signaling promotes Schlemm's canal formation to prevent intraocular hypertension and glaucomatous optic neuropathy. Cell Rep 2024; 43:113799. [PMID: 38367239 DOI: 10.1016/j.celrep.2024.113799] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2023] [Revised: 12/13/2023] [Accepted: 01/31/2024] [Indexed: 02/19/2024] Open
Abstract
Schlemm's canal (SC) functions to maintain proper intraocular pressure (IOP) by draining aqueous humor and has emerged as a promising therapeutic target for glaucoma, the second-leading cause of irreversible blindness worldwide. However, our current understanding of the mechanisms governing SC development and functionality remains limited. Here, we show that vitronectin (VTN) produced by limbal macrophages promotes SC formation and prevents intraocular hypertension by activating integrin αvβ3 signaling. Genetic inactivation of this signaling system inhibited the phosphorylation of AKT and FOXO1 and reduced β-catenin activity and FOXC2 expression, thereby causing impaired Prox1 expression and deteriorated SC morphogenesis. This ultimately led to increased IOP and glaucomatous optic neuropathy. Intriguingly, we found that aged SC displayed downregulated integrin β3 in association with dampened Prox1 expression. Conversely, FOXO1 inhibition rejuvenated the aged SC by inducing Prox1 expression and SC regrowth, highlighting a possible strategy by targeting VTN/integrin αvβ3 signaling to improve SC functionality.
Collapse
Affiliation(s)
- Xinyu Gu
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Xun Chen
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Xuan Zhang
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Keli Liu
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Jing-Jing Li
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Wenyu Lv
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510060, China
| | - Lei Zeng
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Mingjuan Wu
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Weibin Zhou
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou 510060, China
| | - Weifa Wang
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Shunhua Shi
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Yicheng Deng
- School of Medicine, Sun Yat-sen University, Guangzhou 510060, China
| | - Yunhua Li
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Xinbo Gao
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Rong Ju
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Alexandre Dubrac
- Centre de Recherche, CHU St. Justine, Montréal, QC, Canada; Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC, Canada
| | - Xialin Liu
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China
| | - Feng Zhang
- State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou 510060, China.
| |
Collapse
|
5
|
Künzel SH, Pohlmann D, Bonsen LZ, Krappitz M, Zeitz O, Joussen AM, Dubrac A, Künzel SE. Transcriptome Analysis of Choroidal Endothelium Links Androgen Receptor Role to Central Serous Chorioretinopathy. Eur J Ophthalmol 2024:11206721241226735. [PMID: 38263930 DOI: 10.1177/11206721241226735] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/25/2024]
Abstract
BACKGROUND Central Serous Chorioretinopathy (CSCR) manifests as fluid accumulation between the neurosensory retina and the retinal pigment epithelium (RPE). Elevated levels of steroid hormones have been implicated in CSCR pathogenesis. This investigation aims to delineate the gene expression patterns of CSCR-associated risk and steroid receptors across human choroidal cell types and RPE cells to discern potential underlying mechanisms. METHODS This study utilized a comprehensive query of transcriptomic data derived from non-pathological human choroid and RPE cells. FINDINGS CSCR-associated genes such as PTPRB, CFH, and others are predominantly expressed in the choroidal endothelium as opposed to the RPE. The androgen receptor, encoded by the AR gene, demonstrates heightened expression in the macular endothelium compared to peripheral regions, unlike other steroid receptor genes. AR-expressing endothelial cells display an augmented responsiveness to Transforming growth factor beta (TGF-β), indicating a propensity towards endothelial to mesenchymal transition (endMT) transcriptional profiling. INTERPRETATION These results highlight the proclivity of CSCR to manifest primarily within the choroidal vasculature rather than the RPE, suggesting its categorization as a vascular eye disorder. This study accentuates the pivotal role of androgenic steroids, in addition to glucocorticoids. The observed linkage to TGF-β-mediated endMT provides a potential mechanistic insight into the disease's etiology.
Collapse
Affiliation(s)
| | - Dominika Pohlmann
- Department of Ophthalmology, Charité University Hospital Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Lynn Zur Bonsen
- Department of Ophthalmology, Charité University Hospital Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Matteus Krappitz
- Department of Nephrology and Medical Intensive Care, Charité University Hospital Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Oliver Zeitz
- Department of Ophthalmology, Charité University Hospital Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Antonia M Joussen
- Department of Ophthalmology, Charité University Hospital Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
| | - Alexandre Dubrac
- Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, Quebec, Canada
| | - Steffen E Künzel
- Department of Ophthalmology, Charité University Hospital Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany
- Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, Quebec, Canada
| |
Collapse
|
6
|
Künzel SE, Flesch LTM, Frentzel DP, Knecht VA, Rübsam A, Dreher F, Schütte M, Dubrac A, Lange B, Yaspo ML, Lehrach H, Joussen AM, Zeitz O. Systemic Blood Proteome Patterns Reflect Disease Phenotypes in Neovascular Age-Related Macular Degeneration. Int J Mol Sci 2023; 24:10327. [PMID: 37373474 DOI: 10.3390/ijms241210327] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Revised: 05/31/2023] [Accepted: 06/09/2023] [Indexed: 06/29/2023] Open
Abstract
There is early evidence of extraocular systemic signals effecting function and morphology in neovascular age-related macular degeneration (nAMD). The prospective, cross-sectional BIOMAC study is an explorative investigation of peripheral blood proteome profiles and matched clinical features to uncover systemic determinacy in nAMD under anti-vascular endothelial growth factor intravitreal therapy (anti-VEGF IVT). It includes 46 nAMD patients stratified by the level of disease control under ongoing anti-VEGF treatment. Proteomic profiles in peripheral blood samples of every patient were detected with LC-MS/MS mass spectrometry. The patients underwent extensive clinical examination with a focus on macular function and morphology. In silico analysis includes unbiased dimensionality reduction and clustering, a subsequent annotation of clinical features, and non-linear models for recognition of underlying patterns. The model assessment was performed using leave-one-out cross validation. The findings provide an exploratory demonstration of the link between systemic proteomic signals and macular disease pattern using and validating non-linear classification models. Three main results were obtained: (1) Proteome-based clustering identifies two distinct patient subclusters with the smaller one (n = 10) exhibiting a strong signature for oxidative stress response. Matching the relevant meta-features on the individual patient's level identifies pulmonary dysfunction as an underlying health condition in these patients. (2) We identify biomarkers for nAMD disease features with Aldolase C as a putative factor associated with superior disease control under ongoing anti-VEGF treatment. (3) Apart from this, isolated protein markers are only weakly correlated with nAMD disease expression. In contrast, applying a non-linear classification model identifies complex molecular patterns hidden in a high number of proteomic dimensions determining macular disease expression. In conclusion, so far unconsidered systemic signals in the peripheral blood proteome contribute to the clinically observed phenotype of nAMD, which should be examined in future translational research on AMD.
Collapse
Affiliation(s)
- Steffen E Künzel
- Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
| | - Leonie T M Flesch
- Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
| | - Dominik P Frentzel
- Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
| | - Vitus A Knecht
- Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
| | - Anne Rübsam
- Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
| | - Felix Dreher
- Alacris Theranostics, Max-Planck-Straße 3, 12489 Berlin, Germany
| | - Moritz Schütte
- Alacris Theranostics, Max-Planck-Straße 3, 12489 Berlin, Germany
| | - Alexandre Dubrac
- Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC H3C 3J7, Canada
| | - Bodo Lange
- Alacris Theranostics, Max-Planck-Straße 3, 12489 Berlin, Germany
| | - Marie-Laure Yaspo
- Max-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, 14195 Berlin, Germany
| | - Hans Lehrach
- Max-Planck-Institute for Molecular Genetics, Ihnestrasse 63-73, 14195 Berlin, Germany
| | - Antonia M Joussen
- Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
| | - Oliver Zeitz
- Department of Ophthalmology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Hindenburgdamm 30, 12203 Berlin, Germany
| |
Collapse
|
7
|
Drapé E, Anquetil T, Larrivée B, Dubrac A. Brain arteriovenous malformation in hereditary hemorrhagic telangiectasia: Recent advances in cellular and molecular mechanisms. Front Hum Neurosci 2022; 16:1006115. [PMID: 36504622 PMCID: PMC9729275 DOI: 10.3389/fnhum.2022.1006115] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/29/2022] [Accepted: 10/27/2022] [Indexed: 11/25/2022] Open
Abstract
Hereditary hemorrhagic telangiectasia (HHT) is a genetic disorder characterized by vessel dilatation, such as telangiectasia in skin and mucosa and arteriovenous malformations (AVM) in internal organs such as the gastrointestinal tract, lungs, and brain. AVMs are fragile and tortuous vascular anomalies that directly connect arteries and veins, bypassing healthy capillaries. Mutations in transforming growth factor β (TGFβ) signaling pathway components, such as ENG (ENDOGLIN), ACVRL1 (ALK1), and SMAD4 (SMAD4) genes, account for most of HHT cases. 10-20% of HHT patients develop brain AVMs (bAVMs), which can lead to vessel wall rupture and intracranial hemorrhages. Though the main mutations are known, mechanisms leading to AVM formation are unclear, partially due to lack of animal models. Recent mouse models allowed significant advances in our understanding of AVMs. Endothelial-specific deletion of either Acvrl1, Eng or Smad4 is sufficient to induce AVMs, identifying endothelial cells (ECs) as primary targets of BMP signaling to promote vascular integrity. Loss of ALK1/ENG/SMAD4 signaling is associated with NOTCH signaling defects and abnormal arteriovenous EC differentiation. Moreover, cumulative evidence suggests that AVMs originate from venous ECs with defective flow-migration coupling and excessive proliferation. Mutant ECs show an increase of PI3K/AKT signaling and inhibitors of this signaling pathway rescue AVMs in HHT mouse models, revealing new therapeutic avenues. In this review, we will summarize recent advances and current knowledge of mechanisms controlling the pathogenesis of bAVMs, and discuss unresolved questions.
Collapse
Affiliation(s)
- Elise Drapé
- Centre de Recherche, CHU St. Justine, Montréal, QC, Canada,Département de Pharmacologie et de Physiologie, Université de Montréal, Montréal, QC, Canada
| | - Typhaine Anquetil
- Centre de Recherche, CHU St. Justine, Montréal, QC, Canada,Département De Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC, Canada
| | - Bruno Larrivée
- Département d’Ophtalmologie, Université de Montréal, Montréal, QC, Canada,Centre De Recherche, Hôpital Maisonneuve-Rosemont, Montréal, QC, Canada,*Correspondence: Bruno Larrivée,
| | - Alexandre Dubrac
- Centre de Recherche, CHU St. Justine, Montréal, QC, Canada,Département De Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC, Canada,Département d’Ophtalmologie, Université de Montréal, Montréal, QC, Canada,Alexandre Dubrac,
| |
Collapse
|
8
|
Künzel SE, Bürgel T, Künzel SH, Pohlmann D, Zeitz O, Joussen A, Dubrac A. LOW VULNERABILITY OF THE POSTERIOR EYE SEGMENT TO SARS-COV-2 INFECTION: Chorioretinal SARS-CoV-2 Vulnerability. Retina 2022; 42:236-243. [PMID: 35050927 DOI: 10.1097/iae.0000000000003320] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
PURPOSE Retinal manifestations have been described in COVID-19 patients, but it is unknown whether SARS-CoV-2, the causal agent in COVID-19, can directly infect posterior ocular tissues. Here, we investigate SARS-CoV-2 host factor gene expression levels and their distribution across retinal and choroidal cell types. METHODS Query of single-cell RNA sequencing data from human retina and choroid. RESULTS We find no relevant expression of two key genes involved in SARS-CoV-2 entry, ACE2 and TMPRSS2, in retinal cell types. By contrast, scarce expression levels could be detected in choroidal vascular cells. CONCLUSION Given the current understanding of viral host cell entry, these findings suggest a low vulnerability of the posterior eye segment to SARS-CoV-2 with a potential weak spot in the vasculature, which could play a putative causative role in ocular lesions in COVID-19 patients. This may qualify the vasculature of the human posterior eye segment as an in vivo biomarker for life-threatening vascular occlusions in COVID-19 patients.
Collapse
Affiliation(s)
- Steffen Emil Künzel
- Department of Ophthalmology, Charité University Medicine Berlin, Berlin, Germany
| | - Thore Bürgel
- Center for Digital Health, Berlin Institute of Health (BIH) and Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, Berlin, Germany
| | | | - Dominika Pohlmann
- Department of Ophthalmology, Charité University Medicine Berlin, Berlin, Germany
| | - Oliver Zeitz
- Department of Ophthalmology, Charité University Medicine Berlin, Berlin, Germany
| | - Antonia Joussen
- Department of Ophthalmology, Charité University Medicine Berlin, Berlin, Germany
| | - Alexandre Dubrac
- Centre de Recherche, CHU St. Justine, Montréal, Quebec, Canada; and
- Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, Quebec, Canada
| |
Collapse
|
9
|
Li J, Geraldo LH, Dubrac A, Zarkada G, Eichmann A. Slit2-Robo Signaling Promotes Glomerular Vascularization and Nephron Development. J Am Soc Nephrol 2021; 32:2255-2272. [PMID: 34341180 PMCID: PMC8729857 DOI: 10.1681/asn.2020111640] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2020] [Accepted: 04/22/2021] [Indexed: 02/04/2023] Open
Abstract
BACKGROUND Kidney function requires continuous blood filtration by glomerular capillaries. Disruption of glomerular vascular development or maintenance contributes to the pathogenesis of kidney diseases, but the signaling events regulating renal endothelium development remain incompletely understood. Here, we discovered a novel role of Slit2-Robo signaling in glomerular vascularization. Slit2 is a secreted polypeptide that binds to transmembrane Robo receptors and regulates axon guidance as well as ureteric bud branching and angiogenesis. METHODS We performed Slit2-alkaline phosphatase binding to kidney cryosections from mice with or without tamoxifen-inducible Slit2 or Robo1 and -2 deletions, and we characterized the phenotypes using immunohistochemistry, electron microscopy, and functional intravenous dye perfusion analysis. RESULTS Only the glomerular endothelium, but no other renal endothelial compartment, responded to Slit2 in the developing kidney vasculature. Induced Slit2 gene deletion or Slit2 ligand trap at birth affected nephrogenesis and inhibited vascularization of developing glomeruli by reducing endothelial proliferation and migration, leading to defective cortical glomerular perfusion and abnormal podocyte differentiation. Global and endothelial-specific Robo deletion showed that both endothelial and epithelial Robo receptors contributed to glomerular vascularization. CONCLUSIONS Our study provides new insights into the signaling pathways involved in glomerular vascular development and identifies Slit2 as a potential tool to enhance glomerular angiogenesis.
Collapse
Affiliation(s)
- Jinyu Li
- Department of Cellular and Molecular Physiology, Yale University Medical School, New Haven, Connecticut
- Cardiovascular Research Center, Department of Internal Medicine, Yale University, New Haven, Connecticut
| | - Luiz Henrique Geraldo
- Cardiovascular Research Center, Department of Internal Medicine, Yale University, New Haven, Connecticut
- Université de Paris, Paris Cardiovascular Research Center, Institut National de la Santé et de la Recherche Médicale U907, Paris, France
| | - Alexandre Dubrac
- Cardiovascular Research Center, Department of Internal Medicine, Yale University, New Haven, Connecticut
| | - Georgia Zarkada
- Cardiovascular Research Center, Department of Internal Medicine, Yale University, New Haven, Connecticut
| | - Anne Eichmann
- Department of Cellular and Molecular Physiology, Yale University Medical School, New Haven, Connecticut
- Cardiovascular Research Center, Department of Internal Medicine, Yale University, New Haven, Connecticut
- Université de Paris, Paris Cardiovascular Research Center, Institut National de la Santé et de la Recherche Médicale U907, Paris, France
| |
Collapse
|
10
|
Zarkada G, Howard JP, Xiao X, Park H, Bizou M, Leclerc S, Künzel SE, Boisseau B, Li J, Cagnone G, Joyal JS, Andelfinger G, Eichmann A, Dubrac A. Specialized endothelial tip cells guide neuroretina vascularization and blood-retina-barrier formation. Dev Cell 2021; 56:2237-2251.e6. [PMID: 34273276 PMCID: PMC9951594 DOI: 10.1016/j.devcel.2021.06.021] [Citation(s) in RCA: 37] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2021] [Revised: 04/21/2021] [Accepted: 06/25/2021] [Indexed: 02/08/2023]
Abstract
Endothelial tip cells guiding tissue vascularization are primary targets for angiogenic therapies. Whether tip cells require differential signals to develop their complex branching patterns remained unknown. Here, we show that diving tip cells invading the mouse neuroretina (D-tip cells) are distinct from tip cells guiding the superficial retinal vascular plexus (S-tip cells). D-tip cells have a unique transcriptional signature, including high TGF-β signaling, and they begin to acquire blood-retina barrier properties. Endothelial deletion of TGF-β receptor I (Alk5) inhibits D-tip cell identity acquisition and deep vascular plexus formation. Loss of endothelial ALK5, but not of the canonical SMAD effectors, leads to aberrant contractile pericyte differentiation and hemorrhagic vascular malformations. Oxygen-induced retinopathy vasculature exhibits S-like tip cells, and Alk5 deletion impedes retina revascularization. Our data reveal stage-specific tip cell heterogeneity as a requirement for retinal vascular development and suggest that non-canonical-TGF-β signaling could improve retinal revascularization and neural function in ischemic retinopathy.
Collapse
Affiliation(s)
- Georgia Zarkada
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511, USA
| | - Joel P. Howard
- Centre de Recherche, CHU St. Justine, Montréal, QC H3T 1C5, Canada,These authors contributed equally
| | - Xue Xiao
- Centre de Recherche, CHU St. Justine, Montréal, QC H3T 1C5, Canada,Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC H3T 1J4, Canada,These authors contributed equally
| | - Hyojin Park
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511, USA
| | - Mathilde Bizou
- Centre de Recherche, CHU St. Justine, Montréal, QC H3T 1C5, Canada,Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC H3T 1J4, Canada
| | - Severine Leclerc
- Centre de Recherche, CHU St. Justine, Montréal, QC H3T 1C5, Canada
| | - Steffen E. Künzel
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511, USA
| | - Blanche Boisseau
- Centre de Recherche, CHU St. Justine, Montréal, QC H3T 1C5, Canada
| | - Jinyu Li
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511, USA
| | - Gael Cagnone
- Centre de Recherche, CHU St. Justine, Montréal, QC H3T 1C5, Canada
| | | | | | - Anne Eichmann
- Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06511, USA; Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT 06520, USA.
| | - Alexandre Dubrac
- Centre de Recherche, CHU St. Justine, Montréal, QC H3T 1C5, Canada; Département de Pathologie et Biologie Cellulaire, Université de Montréal, Montréal, QC H3T 1J4, Canada.
| |
Collapse
|
11
|
Ola R, Künzel SH, Zhang F, Genet G, Chakraborty R, Pibouin-Fragner L, Martin K, Sessa W, Dubrac A, Eichmann A. SMAD4 Prevents Flow Induced Arteriovenous Malformations by Inhibiting Casein Kinase 2. Circulation 2019; 138:2379-2394. [PMID: 29976569 DOI: 10.1161/circulationaha.118.033842] [Citation(s) in RCA: 71] [Impact Index Per Article: 14.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Hereditary hemorrhagic telangiectasia (HHT) is an inherited vascular disorder that causes arteriovenous malformations (AVMs). Mutations in the genes encoding Endoglin ( ENG) and activin-receptor-like kinase 1 ( AVCRL1 encoding ALK1) cause HHT type 1 and 2, respectively. Mutations in the SMAD4 gene are present in families with juvenile polyposis-HHT syndrome that involves AVMs. SMAD4 is a downstream effector of transforming growth factor-β (TGFβ)/bone morphogenetic protein (BMP) family ligands that signal via activin-like kinase receptors (ALKs). Ligand-neutralizing antibodies or inducible, endothelial-specific Alk1 deletion induce AVMs in mouse models as a result of increased PI3K (phosphatidylinositol 3-kinase)/AKT (protein kinase B) signaling. Here we addressed if SMAD4 was required for BMP9-ALK1 effects on PI3K/AKT pathway activation. METHODS The authors generated tamoxifen-inducible, postnatal, endothelial-specific Smad4 mutant mice ( Smad4iΔEC). RESULTS We found that loss of endothelial Smad4 resulted in AVM formation and lethality. AVMs formed in regions with high blood flow in developing retinas and other tissues. Mechanistically, BMP9 signaling antagonized flow-induced AKT activation in an ALK1- and SMAD4-dependent manner. Smad4iΔEC endothelial cells in AVMs displayed increased PI3K/AKT signaling, and pharmacological PI3K inhibitors or endothelial Akt1 deletion both rescued AVM formation in Smad4iΔEC mice. BMP9-induced SMAD4 inhibited casein kinase 2 ( CK2) transcription, in turn limiting PTEN phosphorylation and AKT activation. Consequently, CK2 inhibition prevented AVM formation in Smad4iΔEC mice. CONCLUSIONS Our study reveals SMAD4 as an essential effector of BMP9-10/ALK1 signaling that affects AVM pathogenesis via regulation of CK2 expression and PI3K/AKT1 activation.
Collapse
Affiliation(s)
- Roxana Ola
- Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut.,Functional Genomics, Proteomics and Experimental Pathology Department, Prof. Dr. I. Chiricuta Oncology Institute, Cluj-Napoca, Romania (R.O.).,Research Center for Functional Genomics, Biomedicine and Translational Medicine, I. Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania (R.O.).,Department of Basic, Preventive and Clinical Science, University of Transylvania, Brasov, Romania (R.O.)
| | - Sandrine H Künzel
- Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut
| | - Feng Zhang
- Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut
| | - Gael Genet
- Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut
| | - Raja Chakraborty
- Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut
| | | | - Kathleen Martin
- Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut
| | - William Sessa
- Vascular Biology and Therapeutics Program, Department of Pharmacology (W.S.), Yale University School of Medicine, New Haven, Connecticut
| | - Alexandre Dubrac
- Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut
| | - Anne Eichmann
- Cardiovascular Research Center, Department of Internal Medicine (R.O., S.H.K., F.Z., G.G., R.C., K.M., A.D., A.E.), Yale University School of Medicine, New Haven, Connecticut.,Department of Cellular and Molecular Physiology (A.E.), Yale University School of Medicine, New Haven, Connecticut.,Inserm U970, Paris Cardiovascular Research Center, Paris, France (L.P-F., A.E.)
| |
Collapse
|
12
|
Genet G, Boyé K, Mathivet T, Ola R, Zhang F, Dubrac A, Li J, Genet N, Henrique Geraldo L, Benedetti L, Künzel S, Pibouin-Fragner L, Thomas JL, Eichmann A. Endophilin-A2 dependent VEGFR2 endocytosis promotes sprouting angiogenesis. Nat Commun 2019; 10:2350. [PMID: 31138815 PMCID: PMC6538628 DOI: 10.1038/s41467-019-10359-x] [Citation(s) in RCA: 49] [Impact Index Per Article: 9.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/04/2018] [Accepted: 04/30/2019] [Indexed: 12/17/2022] Open
Abstract
Endothelial cell migration, proliferation and survival are triggered by VEGF-A activation of VEGFR2. However, how these cell behaviors are regulated individually is still unknown. Here we identify Endophilin-A2 (ENDOA2), a BAR-domain protein that orchestrates CLATHRIN-independent internalization, as a critical mediator of endothelial cell migration and sprouting angiogenesis. We show that EndoA2 knockout mice exhibit postnatal angiogenesis defects and impaired front-rear polarization of sprouting tip cells. ENDOA2 deficiency reduces VEGFR2 internalization and inhibits downstream activation of the signaling effector PAK but not ERK, thereby affecting front-rear polarity and migration but not proliferation or survival. Mechanistically, VEGFR2 is directed towards ENDOA2-mediated endocytosis by the SLIT2-ROBO pathway via SLIT-ROBO-GAP1 bridging of ENDOA2 and ROBO1. Blocking ENDOA2-mediated endothelial cell migration attenuates pathological angiogenesis in oxygen-induced retinopathy models. This work identifies a specific endocytic pathway controlling a subset of VEGFR2 mediated responses that could be targeted to prevent excessive sprouting angiogenesis in pathological conditions.
Collapse
Affiliation(s)
- Gael Genet
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Kevin Boyé
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Thomas Mathivet
- Inserm U970, Paris Cardiovascular Research Center, Paris, 75015, France
| | - Roxana Ola
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
- Functional Genomics, Proteomics and Experimental Pathology Department, Prof. Dr. I. Chiricuta Oncology Institute, Cluj-Napoca, Romania, Department of Basic, Preventive and Clinical Science, University of Transylvania, Brasov, Romania
| | - Feng Zhang
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Alexandre Dubrac
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Jinyu Li
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Nafiisha Genet
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
| | | | - Lorena Benedetti
- Department of Neuroscience and Cell Biology, School of Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Steffen Künzel
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
| | | | - Jean-Leon Thomas
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA
- Department of Neurology, Yale University School of Medicine, New Haven, CT, 06511, USA
- Sorbonne Universités, UPMC Université Paris 06, Institut National de la Santé et de la Recherche Médicale U1127, Centre National de la Recherche Scientifique, AP-HP, Institut du Cerveau et de la Moelle Epinière, Hôpital Pitié-Salpêtrière, Paris, France
| | - Anne Eichmann
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, 06511, USA.
- Inserm U970, Paris Cardiovascular Research Center, Paris, 75015, France.
- Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, 06511, USA.
| |
Collapse
|
13
|
Zhang F, Zarkada G, Han J, Li J, Dubrac A, Ola R, Genet G, Boyé K, Michon P, Künzel SE, Camporez JP, Singh AK, Fong GH, Simons M, Tso P, Fernández-Hernando C, Shulman GI, Sessa WC, Eichmann A. Lacteal junction zippering protects against diet-induced obesity. Science 2018; 361:599-603. [PMID: 30093598 DOI: 10.1126/science.aap9331] [Citation(s) in RCA: 172] [Impact Index Per Article: 28.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2017] [Revised: 04/04/2018] [Accepted: 06/27/2018] [Indexed: 12/18/2022]
Abstract
Excess dietary lipid uptake causes obesity, a major global health problem. Enterocyte-absorbed lipids are packaged into chylomicrons, which enter the bloodstream through intestinal lymphatic vessels called lacteals. Here, we show that preventing lacteal chylomicron uptake by inducible endothelial genetic deletion of Neuropilin1 (Nrp1) and Vascular endothelial growth factor receptor 1 (Vegfr1; also known as Flt1) renders mice resistant to diet-induced obesity. Absence of NRP1 and FLT1 receptors increased VEGF-A bioavailability and signaling through VEGFR2, inducing lacteal junction zippering and chylomicron malabsorption. Restoring permeable lacteal junctions by VEGFR2 and vascular endothelial (VE)-cadherin signaling inhibition rescued chylomicron transport in the mutant mice. Zippering of lacteal junctions by disassembly of cytoskeletal VE-cadherin anchors prevented chylomicron uptake in wild-type mice. These data suggest that lacteal junctions may be targets for preventing dietary fat uptake.
Collapse
Affiliation(s)
- Feng Zhang
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Georgia Zarkada
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Jinah Han
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Jinyu Li
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Alexandre Dubrac
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Roxana Ola
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA.,Department of Basic, Preventive and Clinical Science, University of Transylvania, 500019 Brasov, Romania
| | - Gael Genet
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Kevin Boyé
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Pauline Michon
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA.,INSERM U970, Paris Cardiovascular Research Center, 75015 Paris, France
| | - Steffen E Künzel
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Joao Paulo Camporez
- Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA
| | - Abhishek K Singh
- Departments of Comparative Medicine and Pathology, Vascular Biology and Therapeutics Program and Integrative Cell Signaling and Neurobiology of Metabolism Program, Yale University School of Medicine, New Haven, CT, USA
| | - Guo-Hua Fong
- Department of Cell Biology, University of Connecticut Health Center, Farmington, CT, 06030-3501, USA
| | - Michael Simons
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA
| | - Patrick Tso
- Department of Pathology and Laboratory Medicine, Metabolic Diseases Institute, University of Cincinnati, Cincinnati, OH 45237-0507, USA
| | - Carlos Fernández-Hernando
- Departments of Comparative Medicine and Pathology, Vascular Biology and Therapeutics Program and Integrative Cell Signaling and Neurobiology of Metabolism Program, Yale University School of Medicine, New Haven, CT, USA
| | - Gerald I Shulman
- Department of Internal Medicine, Yale University School of Medicine, New Haven, CT, USA.,Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA
| | - William C Sessa
- Department of Pharmacology, Vascular Biology and Therapeutics Program, Yale University School of Medicine, New Haven, CT, USA
| | - Anne Eichmann
- Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06510-3221, USA. .,INSERM U970, Paris Cardiovascular Research Center, 75015 Paris, France.,Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, USA
| |
Collapse
|
14
|
Dubrac A, Künzel SE, Künzel SH, Li J, Chandran RR, Martin K, Greif DM, Adams RH, Eichmann A. NCK-dependent pericyte migration promotes pathological neovascularization in ischemic retinopathy. Nat Commun 2018; 9:3463. [PMID: 30150707 PMCID: PMC6110853 DOI: 10.1038/s41467-018-05926-7] [Citation(s) in RCA: 46] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2017] [Accepted: 07/04/2018] [Indexed: 12/20/2022] Open
Abstract
Pericytes are mural cells that surround capillaries and control angiogenesis and capillary barrier function. During sprouting angiogenesis, endothelial cell-derived platelet-derived growth factor-B (PDGF-B) regulates pericyte proliferation and migration via the platelet-derived growth factor receptor-β (PDGFRβ). PDGF-B overexpression has been associated with proliferative retinopathy, but the underlying mechanisms remain poorly understood. Here we show that abnormal, α-SMA-expressing pericytes cover angiogenic sprouts and pathological neovascular tufts (NVTs) in a mouse model of oxygen-induced retinopathy. Genetic lineage tracing demonstrates that pericytes acquire α-SMA expression during NVT formation. Pericyte depletion through inducible endothelial-specific knockout of Pdgf-b decreases NVT formation and impairs revascularization. Inactivation of the NCK1 and NCK2 adaptor proteins inhibits pericyte migration by preventing PDGF-B-induced phosphorylation of PDGFRβ at Y1009 and PAK activation. Loss of Nck1 and Nck2 in mural cells prevents NVT formation and vascular leakage and promotes revascularization, suggesting PDGFRβ-Y1009/NCK signaling as a potential target for the treatment of retinopathies. Pericytes are perivascular cells that regulate blood vessel formation and function. Here Dubrac et al. show that pericyte recruitment contributes to pathological neovascularisation in a mouse model of ischemic retinopathy, and that this depends on the regulation of PDGF-B signaling by NCK adaptor proteins.
Collapse
Affiliation(s)
- Alexandre Dubrac
- Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, 06511, USA.
| | - Steffen E Künzel
- Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Sandrine H Künzel
- Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Jinyu Li
- Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Rachana Radhamani Chandran
- Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Kathleen Martin
- Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Daniel M Greif
- Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, 06511, USA
| | - Ralf H Adams
- Department of Tissue Morphogenesis and University of Münster, Faculty of Medicine, Max Planck Institute for Molecular Biomedicine, 48149, Münster, Germany
| | - Anne Eichmann
- Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT, 06511, USA. .,INSERM U970, Paris Cardiovascular Research Center, 75015, Paris, France. .,Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT, 06520, USA.
| |
Collapse
|
15
|
|
16
|
Yu P, Wilhelm K, Dubrac A, Tung JK, Alves TC, Fang JS, Xie Y, Zhu J, Chen Z, De Smet F, Zhang J, Jin SW, Sun L, Sun H, Kibbey RG, Hirschi KK, Hay N, Carmeliet P, Chittenden TW, Eichmann A, Potente M, Simons M. FGF-dependent metabolic control of vascular development. Nature 2017; 545:224-228. [PMID: 28467822 PMCID: PMC5427179 DOI: 10.1038/nature22322] [Citation(s) in RCA: 223] [Impact Index Per Article: 31.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/28/2015] [Accepted: 03/29/2017] [Indexed: 12/22/2022]
Abstract
Blood and lymphatic vasculatures are intimately involved in tissue oxygenation and fluid homeostasis maintenance. Assembly of these vascular networks involves sprouting, migration and proliferation of endothelial cells. Recent studies have suggested that changes in cellular metabolism are important to these processes. Although much is known about vascular endothelial growth factor (VEGF)-dependent regulation of vascular development and metabolism, little is understood about the role of fibroblast growth factors (FGFs) in this context. Here we identify FGF receptor (FGFR) signalling as a critical regulator of vascular development. This is achieved by FGF-dependent control of c-MYC (MYC) expression that, in turn, regulates expression of the glycolytic enzyme hexokinase 2 (HK2). A decrease in HK2 levels in the absence of FGF signalling inputs results in decreased glycolysis, leading to impaired endothelial cell proliferation and migration. Pan-endothelial- and lymphatic-specific Hk2 knockouts phenocopy blood and/or lymphatic vascular defects seen in Fgfr1/Fgfr3 double mutant mice, while HK2 overexpression partly rescues the defects caused by suppression of FGF signalling. Thus, FGF-dependent regulation of endothelial glycolysis is a pivotal process in developmental and adult vascular growth and development.
Collapse
MESH Headings
- Animals
- Cell Movement
- Cell Proliferation
- Endothelial Cells/cytology
- Endothelial Cells/metabolism
- Female
- Fibroblast Growth Factors/metabolism
- Glycolysis
- Hexokinase/metabolism
- Lymphangiogenesis
- Lymphatic Vessels/cytology
- Lymphatic Vessels/metabolism
- Mice
- Mice, Inbred C57BL
- Neovascularization, Physiologic
- Proto-Oncogene Proteins c-myc/metabolism
- Receptor, Fibroblast Growth Factor, Type 1/deficiency
- Receptor, Fibroblast Growth Factor, Type 1/genetics
- Receptor, Fibroblast Growth Factor, Type 1/metabolism
- Receptor, Fibroblast Growth Factor, Type 3/deficiency
- Receptor, Fibroblast Growth Factor, Type 3/genetics
- Receptor, Fibroblast Growth Factor, Type 3/metabolism
- Signal Transduction
Collapse
Affiliation(s)
- Pengchun Yu
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
| | - Kerstin Wilhelm
- Angiogenesis & Metabolism Laboratory, Max Plank Institute for Heart and Lung Research, D-61231 Bad Nauheim, Germany
| | - Alexandre Dubrac
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
| | - Joe K. Tung
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
| | - Tiago C. Alves
- Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine
| | - Jennifer S. Fang
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
| | - Yi Xie
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
| | - Jie Zhu
- Department of Cellular and Molecular Physiology, Yale University School of Medicine
| | - Zehua Chen
- Computational Statistics and Bioinformatics Group, Advanced Artificial Intelligence Research Laboratory, WuXi NextCODE, Cambridge, MA, USA
| | - Frederik De Smet
- Switch Laboratory, VIB-KU Leuven, Leuven, B-3000, Belgium
- Center for Molecular Oncologic Pathology, Dana-Farber Cancer Institute, Boston, MA 02215, USA
| | - Jiasheng Zhang
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
| | - Suk-Won Jin
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
- School of Life Sciences, Gwangju Institute of Science and Technology, Gwangju, Korea
| | - Lele Sun
- Genomics Laboratory, WuXi NextCODE, Shanghai, China
| | - Hongye Sun
- Genomics Laboratory, WuXi NextCODE, Shanghai, China
| | - Richard G. Kibbey
- Section of Endocrinology, Department of Internal Medicine, Yale University School of Medicine
| | - Karen K. Hirschi
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
| | - Nissim Hay
- Department of Biochemistry and Molecular Genetics, College of Medicine, University of Illinois at Chicago
| | - Peter Carmeliet
- Laboratory of Angiogenesis and Neurovascular Link, Department of Oncology, University of Leuven, Leuven, B-3000, Belgium
- Laboratory of Angiogenesis and Neurovascular Link, Vesalius Research Center, VIB, Leuven, B-3000, Belgium
| | - Thomas W. Chittenden
- Computational Statistics and Bioinformatics Group, Advanced Artificial Intelligence Research Laboratory, WuXi NextCODE, Cambridge, MA, USA
| | - Anne Eichmann
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
- U970, Paris Cardiovascular Research Center, 56 Rue Leblanc, 75015 Paris, France
| | - Michael Potente
- Angiogenesis & Metabolism Laboratory, Max Plank Institute for Heart and Lung Research, D-61231 Bad Nauheim, Germany
| | - Michael Simons
- Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, USA
- Department of Cell Biology, Yale University School of Medicine, New Haven, CT
| |
Collapse
|
17
|
Ola R, Dubrac A, Han J, Zhang F, Fang JS, Larrivée B, Lee M, Urarte AA, Kraehling JR, Genet G, Hirschi KK, Sessa WC, Canals FV, Graupera M, Yan M, Young LH, Oh PS, Eichmann A. PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia. Nat Commun 2016; 7:13650. [PMID: 27897192 PMCID: PMC5141347 DOI: 10.1038/ncomms13650] [Citation(s) in RCA: 112] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2016] [Accepted: 10/20/2016] [Indexed: 12/26/2022] Open
Abstract
Activin receptor-like kinase 1 (ALK1) is an endothelial serine-threonine kinase receptor for bone morphogenetic proteins (BMPs) 9 and 10. Inactivating mutations in the ALK1 gene cause hereditary haemorrhagic telangiectasia type 2 (HHT2), a disabling disease characterized by excessive angiogenesis with arteriovenous malformations (AVMs). Here we show that inducible, endothelial-specific homozygous Alk1 inactivation and BMP9/10 ligand blockade both lead to AVM formation in postnatal retinal vessels and internal organs including the gastrointestinal (GI) tract in mice. VEGF and PI3K/AKT signalling are increased on Alk1 deletion and BMP9/10 ligand blockade. Genetic deletion of the signal-transducing Vegfr2 receptor prevents excessive angiogenesis but does not fully revert AVM formation. In contrast, pharmacological PI3K inhibition efficiently prevents AVM formation and reverts established AVMs. Thus, Alk1 deletion leads to increased endothelial PI3K pathway activation that may be a novel target for the treatment of vascular lesions in HHT2.
Collapse
Affiliation(s)
- Roxana Ola
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Alexandre Dubrac
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Jinah Han
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Feng Zhang
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Jennifer S. Fang
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Bruno Larrivée
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Monica Lee
- Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
| | - Ana A. Urarte
- Vascular Signalling Laboratory, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona 08908, Spain
| | - Jan R. Kraehling
- Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
| | - Gael Genet
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Karen K. Hirschi
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - William C. Sessa
- Department of Pharmacology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
| | - Francesc V. Canals
- Translation Research Laboratory, Catalan Institute of Oncology, Idibell, Barcelona 08908, Spain
| | - Mariona Graupera
- Vascular Signalling Laboratory, Institut d'Investigació Biomèdica de Bellvitge, L'Hospitalet de Llobregat, Barcelona 08908, Spain
| | - Minhong Yan
- Molecular Oncology, Genentech, Inc., South San Francisco, California 94080-4990, USA
| | - Lawrence H. Young
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
| | - Paul S. Oh
- Department of Physiology and Functional Genomics, University of Florida College of Medicine, PO Box 100274, Gainesville, Florida 32610, USA
| | - Anne Eichmann
- Cardiovascular Research Center, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut 06511, USA
- Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut 06520, USA
- Inserm U970, Paris Cardiovascular Research Center, Paris 75015, France
| |
Collapse
|
18
|
Baeyens N, Larrivée B, Ola R, Hayward-Piatkowskyi B, Dubrac A, Huang B, Ross TD, Coon BG, Min E, Tsarfati M, Tong H, Eichmann A, Schwartz MA. Defective fluid shear stress mechanotransduction mediates hereditary hemorrhagic telangiectasia. J Cell Biol 2016; 214:807-16. [PMID: 27646277 PMCID: PMC5037412 DOI: 10.1083/jcb.201603106] [Citation(s) in RCA: 117] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/30/2016] [Accepted: 08/30/2016] [Indexed: 11/27/2022] Open
Abstract
Mutations of the endothelial BMP9/10 receptors Alk1 and endoglin are associated with vascular malformations in hereditary hemorrhagic telangiectasia (HHT). Baeyens et al. report that fluid flow potentiates BMP activation of Alk1 signaling to stabilize blood vessels. HHT lesions thus result from a defect in a synergistic mechanical/biochemical signaling pathway. Morphogenesis of the vascular system is strongly modulated by mechanical forces from blood flow. Hereditary hemorrhagic telangiectasia (HHT) is an inherited autosomal-dominant disease in which arteriovenous malformations and telangiectasias accumulate with age. Most cases are linked to heterozygous mutations in Alk1 or Endoglin, receptors for bone morphogenetic proteins (BMPs) 9 and 10. Evidence suggests that a second hit results in clonal expansion of endothelial cells to form lesions with poor mural cell coverage that spontaneously rupture and bleed. We now report that fluid shear stress potentiates BMPs to activate Alk1 signaling, which correlates with enhanced association of Alk1 and endoglin. Alk1 is required for BMP9 and flow responses, whereas endoglin is only required for enhancement by flow. This pathway mediates both inhibition of endothelial proliferation and recruitment of mural cells; thus, its loss blocks flow-induced vascular stabilization. Identification of Alk1 signaling as a convergence point for flow and soluble ligands provides a molecular mechanism for development of HHT lesions.
Collapse
Affiliation(s)
- Nicolas Baeyens
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Bruno Larrivée
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511 Department of Ophthalmology, Maisonneuve-Rosemont Hospital Research Centre, University of Montreal, Montreal, Quebec H3T 1J4, Canada
| | - Roxana Ola
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Brielle Hayward-Piatkowskyi
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Alexandre Dubrac
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Billy Huang
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Tyler D Ross
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Brian G Coon
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Elizabeth Min
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Maya Tsarfati
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511
| | - Haibin Tong
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT 06511 Jilin Provincial Key Laboratory of Molecular Geriatric Medicine, Life Science Research Center, Beihua University, Jilin 132013, China
| | - Anne Eichmann
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Institut National de la Santé et de la Recherche Médicale U970, Paris Center for Cardiovascular Research, 75015 Paris, France
| | - Martin A Schwartz
- Department of Medicine (Cardiology), Yale University School of Medicine, New Haven, CT 06511 Department of Cell Biology, Yale University, New Haven, CT 06510 Department of Biomedical Engineering, Yale University, New Haven, CT 06510
| |
Collapse
|
19
|
Quemener C, Baud J, Boyé K, Dubrac A, Billottet C, Soulet F, Darlot F, Dumartin L, Sire M, Grepin R, Daubon T, Rayne F, Wodrich H, Couvelard A, Pineau R, Schilling M, Castronovo V, Sue SC, Clarke K, Lomri A, Khatib AM, Hagedorn M, Prats H, Bikfalvi A. Dual Roles for CXCL4 Chemokines and CXCR3 in Angiogenesis and Invasion of Pancreatic Cancer. Cancer Res 2016; 76:6507-6519. [DOI: 10.1158/0008-5472.can-15-2864] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/15/2015] [Revised: 07/09/2016] [Accepted: 08/12/2016] [Indexed: 11/16/2022]
|
20
|
Jabouille A, Delugin M, Pineau R, Dubrac A, Soulet F, Lhomond S, Pallares-Lupon N, Prats H, Bikfalvi A, Chevet E, Touriol C, Moenner M. Glioblastoma invasion and cooption depend on IRE1α endoribonuclease activity. Oncotarget 2016; 6:24922-34. [PMID: 26325176 PMCID: PMC4694804 DOI: 10.18632/oncotarget.4679] [Citation(s) in RCA: 35] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2015] [Accepted: 07/10/2015] [Indexed: 12/19/2022] Open
Abstract
IRE1α is an endoplasmic reticulum (ER)-resident transmembrane signaling protein and a cellular stress sensor. The protein harbors a cytosolic dual kinase/endoribonuclease activity required for adaptive responses to micro-environmental changes. In an orthotopic xenograft model of human glioma, invalidation of IRE1α RNase or/and kinase activities generated tumors with remarkably distinct phenotypes. Contrasting with the extensive angiogenesis observed in tumors derived from control cells, the double kinase/RNase invalidation reprogrammed mesenchymal differentiation of cancer cells and produced avascular and infiltrative glioblastomas with blood vessel co-option. In comparison, selective invalidation of IRE1α RNase did not compromise tumor angiogenesis but still elicited invasive features and vessel co-option. In vitro, IRE1α RNase deficient cells were also endowed with a higher ability to migrate. Constitutive activation of both enzymes led to wild-type-like lesions. The presence of IRE1α, but not its RNase activity, is therefore required for glioblastoma neovascularization, whereas invasion results only from RNase inhibition. In this model, two key mechanisms of tumor progression and cancer cell survival are functionally linked to IRE1α.
Collapse
Affiliation(s)
- Arnaud Jabouille
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France
| | - Maylis Delugin
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France
| | | | | | - Fabienne Soulet
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France
| | - Stéphanie Lhomond
- Université de Bordeaux, 33000 Bordeaux, France.,Inserm, U1053, 33000 Bordeaux, France
| | - Nestor Pallares-Lupon
- Université de Bordeaux, 33000 Bordeaux, France.,Inserm, U1053, 33000 Bordeaux, France
| | - Hervé Prats
- Inserm, U1037, CHU de Rangueil, 31432 Toulouse, France
| | - Andreas Bikfalvi
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France
| | - Eric Chevet
- Université de Bordeaux, 33000 Bordeaux, France.,Inserm, U1053, 33000 Bordeaux, France.,Centre Régional de Lutte Contre le Cancer Eugène Marquis, 35000 Rennes, France.,ER440, Oncogenesis, Stress, Signaling, Université Rennes 1, Rennes, France
| | | | - Michel Moenner
- Inserm, U1029, 33400 Talence, France.,Université de Bordeaux, 33000 Bordeaux, France.,CNRS UMR5095, IBGC, 33700 Bordeaux, France
| |
Collapse
|
21
|
Pardanaud L, Pibouin-Fragner L, Dubrac A, Mathivet T, English I, Brunet I, Simons M, Eichmann A. Sympathetic Innervation Promotes Arterial Fate by Enhancing Endothelial ERK Activity. Circ Res 2016; 119:607-20. [PMID: 27354211 DOI: 10.1161/circresaha.116.308473] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/02/2016] [Accepted: 06/24/2016] [Indexed: 12/31/2022]
Abstract
RATIONALE Arterial endothelial cells are morphologically, functionally, and molecularly distinct from those found in veins and lymphatic vessels. How arterial fate is acquired during development and maintained in adult vessels is incompletely understood. OBJECTIVE We set out to identify factors that promote arterial endothelial cell fate in vivo. METHODS AND RESULTS We developed a functional assay, allowing us to monitor and manipulate arterial fate in vivo, using arteries isolated from quails that are grafted into the coelom of chick embryos. Endothelial cells migrate out from the grafted artery, and their colonization of host arteries and veins is quantified. Here we show that sympathetic innervation promotes arterial endothelial cell fate in vivo. Removal of sympathetic nerves decreases arterial fate and leads to colonization of veins, whereas exposure to sympathetic nerves or norepinephrine imposes arterial fate. Mechanistically, sympathetic nerves increase endothelial ERK (extracellular signal-regulated kinase) activity via adrenergic α1 and α2 receptors. CONCLUSIONS These findings show that sympathetic innervation promotes arterial endothelial fate and may lead to novel approaches to improve arterialization in human disease.
Collapse
Affiliation(s)
- Luc Pardanaud
- From the INSERM U970, Paris Center for Cardiovascular Research (PARCC), Paris, France (L.P., L.P.-F., T.M., A.E.); Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., M.S., A.E.); and INSERM U1050, Collège de France, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Paris, France (I.E., I.B.).
| | - Laurence Pibouin-Fragner
- From the INSERM U970, Paris Center for Cardiovascular Research (PARCC), Paris, France (L.P., L.P.-F., T.M., A.E.); Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., M.S., A.E.); and INSERM U1050, Collège de France, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Paris, France (I.E., I.B.)
| | - Alexandre Dubrac
- From the INSERM U970, Paris Center for Cardiovascular Research (PARCC), Paris, France (L.P., L.P.-F., T.M., A.E.); Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., M.S., A.E.); and INSERM U1050, Collège de France, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Paris, France (I.E., I.B.)
| | - Thomas Mathivet
- From the INSERM U970, Paris Center for Cardiovascular Research (PARCC), Paris, France (L.P., L.P.-F., T.M., A.E.); Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., M.S., A.E.); and INSERM U1050, Collège de France, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Paris, France (I.E., I.B.)
| | - Isabel English
- From the INSERM U970, Paris Center for Cardiovascular Research (PARCC), Paris, France (L.P., L.P.-F., T.M., A.E.); Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., M.S., A.E.); and INSERM U1050, Collège de France, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Paris, France (I.E., I.B.)
| | - Isabelle Brunet
- From the INSERM U970, Paris Center for Cardiovascular Research (PARCC), Paris, France (L.P., L.P.-F., T.M., A.E.); Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., M.S., A.E.); and INSERM U1050, Collège de France, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Paris, France (I.E., I.B.)
| | - Michael Simons
- From the INSERM U970, Paris Center for Cardiovascular Research (PARCC), Paris, France (L.P., L.P.-F., T.M., A.E.); Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., M.S., A.E.); and INSERM U1050, Collège de France, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Paris, France (I.E., I.B.)
| | - Anne Eichmann
- From the INSERM U970, Paris Center for Cardiovascular Research (PARCC), Paris, France (L.P., L.P.-F., T.M., A.E.); Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., M.S., A.E.); and INSERM U1050, Collège de France, Centre Interdisciplinaire de Recherche en Biologie (CIRB), Paris, France (I.E., I.B.).
| |
Collapse
|
22
|
Philippe C, Dubrac A, Quelen C, Desquesnes A, Van Den Berghe L, Ségura C, Filleron T, Pyronnet S, Prats H, Brousset P, Touriol C. PERK mediates the IRES-dependent translational activation of mRNAs encoding angiogenic growth factors after ischemic stress. Sci Signal 2016; 9:ra44. [PMID: 27141928 DOI: 10.1126/scisignal.aaf2753] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Angiogenesis is induced by various conditions, including hypoxia. Although cap-dependent translation is globally inhibited during ischemia, the mRNAs encoding two important proangiogenic growth factors, vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2), are translated at early time points in ischemic muscle. The translation of these mRNAs can occur through internal ribosome entry sites (IRESs), rather than through cap-dependent translation. Hypoxic conditions also induce the unfolded protein response (UPR) and endoplasmic reticulum (ER) stress, leading us to assess the interplay between hypoxia, ER stress, and IRES-mediated translation of FGF-2 and VEGF We found that unlike cap-dependent translation, translation through FGF-2 and VEGF IRESs was efficient in cells and transgenic mice subjected to ER stress-inducing stimuli. We identified PERK, a kinase that is activated by ER stress, as the driver of VEGF and FGF-2 IRES-mediated translation in cells and in mice expressing IRES-driven reporter genes and exposed to hypoxic stress. These results demonstrate the role of IRES-dependent translation in the induction of the proangiogenic factors VEGF and FGF-2 in response to acute hypoxic stress. Furthermore, the PERK pathway could be a viable pharmacological target to improve physiological responses to ischemic situations.
Collapse
Affiliation(s)
- Céline Philippe
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France
| | - Alexandre Dubrac
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France
| | - Cathy Quelen
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France
| | - Aurore Desquesnes
- INSERM US006, CREFRE (Centre régional d'exploration fonctionnelle et de ressources expérimentales), F-31000 Toulouse, France
| | - Loic Van Den Berghe
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France. Vectorology Platform, CRCT Technological Pole, F-31037 Toulouse, France
| | - Christèle Ségura
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France. Vectorology Platform, CRCT Technological Pole, F-31037 Toulouse, France
| | - Thomas Filleron
- Clinical Trial Office, Department of Statistics, IUCT (Institut Universitaire du Cancer de Toulouse)-Oncopole, F-31100 Toulouse, France
| | - Stéphane Pyronnet
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France. Laboratoire d'Excellence Toulouse Cancer (TOUCAN), F-31037 Toulouse, France
| | - Hervé Prats
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France
| | - Pierre Brousset
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France. Laboratoire d'Excellence Toulouse Cancer (TOUCAN), F-31037 Toulouse, France. Department of Pathology, IUCT-Oncopole, F-31100 Toulouse, France
| | - Christian Touriol
- INSERM, UMR 1037, CRCT (Cancer Research Center of Toulouse), F-31037 Toulouse, France. Université Toulouse III Paul Sabatier, F-31000 Toulouse, France.
| |
Collapse
|
23
|
Cammas A, Dubrac A, Morel B, Lamaa A, Touriol C, Teulade-Fichou MP, Prats H, Millevoi S. Stabilization of the G-quadruplex at the VEGF IRES represses cap-independent translation. RNA Biol 2015; 12:320-9. [PMID: 25826664 DOI: 10.1080/15476286.2015.1017236] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023] Open
Abstract
The activation of translation contributes to malignant transformation and is an emerging target for cancer therapies. RNA G-quadruplex structures are general inhibitors of cap-dependent mRNA translation and were recently shown to be targeted for oncoprotein translational activation. In contrast however, the G-quadruplex within the 5'UTR of the human vascular endothelial growth factor A (VEGF) has been shown to be essential for IRES-mediated translation. Since VEGF has a pivotal role in tumor angiogenesis and is a major target of anti-tumoral therapies, we investigated the structure/function relationship of the VEGF G-quadruplex and defined whether it could have a therapeutic potential. We found that the G-quadruplex within the VEGF IRES is dispensable for cap-independent function and activation in stress conditions. However, stabilization of the VEGF G-quadruplex by increasing the G-stretches length or by replacing it with the one of NRAS results in strong inhibition of IRES-mediated translation of VEGF. We also demonstrate that G-quadruplex ligands stabilize the VEGF G-quadruplex and inhibit cap-independent translation in vitro. Importantly, the amount of human VEGF mRNA associated with polysomes decreases in the presence of a highly selective stabilizing G-quadruplex ligand, resulting in reduced VEGF protein expression. Together, our results uncover the existence of functionally silent G-quadruplex structures that are susceptible to conversion into efficient repressors of cap-independent mRNA translation. These findings have implications for the in vivo applications of G-quadruplex-targeting compounds and for anti-angiogenic therapies.
Collapse
Affiliation(s)
- Anne Cammas
- a Inserm UMR 1037- University of Toulouse III; Cancer Research Center of Toulouse (CRCT) ; Toulouse, France
| | | | | | | | | | | | | | | |
Collapse
|
24
|
Dubrac A, Genet G, Ola R, Zhang F, Pibouin-Fragner L, Han J, Zhang J, Thomas JL, Chedotal A, Schwartz MA, Eichmann A. Targeting NCK-Mediated Endothelial Cell Front-Rear Polarity Inhibits Neovascularization. Circulation 2015; 133:409-21. [PMID: 26659946 DOI: 10.1161/circulationaha.115.017537] [Citation(s) in RCA: 52] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2015] [Accepted: 12/04/2015] [Indexed: 12/22/2022]
Abstract
BACKGROUND Sprouting angiogenesis is a key process driving blood vessel growth in ischemic tissues and an important drug target in a number of diseases, including wet macular degeneration and wound healing. Endothelial cells forming the sprout must develop front-rear polarity to allow sprout extension. The adaptor proteins Nck1 and 2 are known regulators of cytoskeletal dynamics and polarity, but their function in angiogenesis is poorly understood. Here, we show that the Nck adaptors are required for endothelial cell front-rear polarity and migration downstream of the angiogenic growth factors VEGF-A and Slit2. METHODS AND RESULTS Mice carrying inducible, endothelial-specific Nck1/2 deletions fail to develop front-rear polarized vessel sprouts and exhibit severe angiogenesis defects in the postnatal retina and during embryonic development. Inactivation of NCK1 and 2 inhibits polarity by preventing Cdc42 and Pak2 activation by VEGF-A and Slit2. Mechanistically, NCK binding to ROBO1 is required for both Slit2- and VEGF-induced front-rear polarity. Selective inhibition of polarized endothelial cell migration by targeting Nck1/2 prevents hypersprouting induced by Notch or Bmp signaling inhibition, and pathological ocular neovascularization and wound healing, as well. CONCLUSIONS These data reveal a novel signal integration mechanism involving NCK1/2, ROBO1/2, and VEGFR2 that controls endothelial cell front-rear polarity during sprouting angiogenesis.
Collapse
Affiliation(s)
- Alexandre Dubrac
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Gael Genet
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Roxana Ola
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Feng Zhang
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Laurence Pibouin-Fragner
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Jinah Han
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Jiasheng Zhang
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Jean-Léon Thomas
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Alain Chedotal
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Martin A Schwartz
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.)
| | - Anne Eichmann
- From Cardiovascular Research Center, Yale University School of Medicine, New Haven, CT (A.D., G.G., R.O., F.Z., J.H., J.Z., J.-L.T., A.E.); INSERM U1050, Collège de France, Center for Interdisciplinary Research in Biology (CIRB), Paris (L.P.-F., A.E.); Department of Neurology, Yale University School of Medicine, New Haven, CT (J.-L.T.); Institut du Cerveau et de la Moelle, Inserm, Université Pierre et Marie Curie, Paris, France (J.-L.T.); Sorbonne Universités, UPMC Universités Paris 06, INSERM, UMR-S968, CNRS, UMR-7210, Institut de la Vision, France (A.C.); Departments of Cell Biology and Biomedical Engineering, Yale University, New Haven, CT (M.A.S.); and Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, CT (A.E.).
| |
Collapse
|
25
|
Rama N, Dubrac A, Mathivet T, Ní Chárthaigh RA, Genet G, Cristofaro B, Pibouin-Fragner L, Ma L, Eichmann A, Chédotal A. Slit2 signaling through Robo1 and Robo2 is required for retinal neovascularization. Nat Med 2015; 21:483-91. [PMID: 25894826 PMCID: PMC4819398 DOI: 10.1038/nm.3849] [Citation(s) in RCA: 115] [Impact Index Per Article: 12.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2014] [Accepted: 03/25/2015] [Indexed: 02/07/2023]
Abstract
Ocular neovascular diseases are a leading cause of blindness. Vascular endothelial growth factor (VEGF) blockade improves vision, but not all individuals respond to anti-VEGF treatment, making additional means to prevent neovascularization necessary. Slit-family proteins (Slits) are ligands of Roundabout (Robo) receptors that repel developing axons in the nervous system. Robo1 expression is altered in ocular neovascular diseases, and previous in vitro studies have reported both pro- and anti-angiogenic effects of Slits. However, genetic evidence supporting a role for Slits in ocular neovascularization is lacking. Here we generated conditional knockout mice deficient in various Slit and Robo proteins and found that Slit2 potently and selectively promoted angiogenesis via Robo1 and Robo2 in mouse postnatal retina and in a model of ocular neovascular disease. Mechanistically, Slit2 acting through Robo1 and Robo2 promoted the migration of endothelial cells. These receptors are required for both Slit2- and VEGF-induced Rac1 activation and lamellipodia formation. Thus, Slit2 blockade could potentially be used therapeutically to inhibit angiogenesis in individuals with ocular neovascular disease.
Collapse
Affiliation(s)
- Nicolas Rama
- 1] INSERM UMR S968, Institut de la Vision, Paris, France. [2] Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. [3] UMR 7210, CNRS, Paris, France
| | - Alexandre Dubrac
- Section of Cardiovascular Medicine, Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Thomas Mathivet
- Center for Interdisciplinary Research in Biology (CIRB), Collège de France, Paris, France
| | - Róisín-Ana Ní Chárthaigh
- 1] INSERM UMR S968, Institut de la Vision, Paris, France. [2] Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. [3] UMR 7210, CNRS, Paris, France
| | - Gael Genet
- Section of Cardiovascular Medicine, Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Brunella Cristofaro
- Center for Interdisciplinary Research in Biology (CIRB), Collège de France, Paris, France
| | | | - Le Ma
- Department of Neuroscience, Farber Institute for Neurosciences, Thomas Jefferson University, Philadelphia, Pennsylvania, USA
| | - Anne Eichmann
- 1] Section of Cardiovascular Medicine, Department of Internal Medicine, Yale Cardiovascular Research Center, Yale University School of Medicine, New Haven, Connecticut, USA. [2] Center for Interdisciplinary Research in Biology (CIRB), Collège de France, Paris, France. [3] Department of Cellular and Molecular Physiology, Yale University School of Medicine, New Haven, Connecticut, USA
| | - Alain Chédotal
- 1] INSERM UMR S968, Institut de la Vision, Paris, France. [2] Université Pierre et Marie Curie, Sorbonne Universités, Paris, France. [3] UMR 7210, CNRS, Paris, France
| |
Collapse
|
26
|
Lanahan AA, Lech D, Dubrac A, Zhang J, Zhuang ZW, Eichmann A, Simons M. PTP1b is a physiologic regulator of vascular endothelial growth factor signaling in endothelial cells. Circulation 2014; 130:902-9. [PMID: 24982127 DOI: 10.1161/circulationaha.114.009683] [Citation(s) in RCA: 76] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
Abstract
BACKGROUND Regulation of vascular endothelial growth factor receptor-2 (VEGFR2) signaling is a control point that determines the extent of vascular tree formation. Recent studies demonstrated an important role played by VEGFR2 endothelial trafficking in control of its activity and suggested the involvement of a phosphotyrosine phosphatase 1b (PTP1b) in this process. This study was designed to define the role of PTP1b in endothelial VEGFR2 signaling and its role in regulation of angiogenesis and arteriogenesis. METHODS AND RESULTS We generated mice carrying an endothelial-specific deletion of PTP1b and examined the effect of this knockout on VEGF signaling, angiogenesis, and arteriogenesis in vitro and in vivo. PTP1b knockout endothelial cells had increased VEGF-dependent activation of extracellular signal-regulated kinase signaling, sprouting, migration, and proliferation compared with controls. Endothelial PTP1b null mice had increased retinal and Matrigel implant angiogenesis and accelerated wound healing, pointing to enhanced angiogenesis. Increased arteriogenesis was demonstrated by observations of faster recovery of arterial blood flow and large numbers of newly formed arterioles in the hindlimb ischemia mouse model. PTP1b endothelial knockout also rescued impaired blood flow recovery after common femoral artery ligation in synectin null mice. CONCLUSIONS PTP1b is a key regulator of endothelial VEGFR2 signaling and plays an important role in regulation of the extent of vascular tree formation.
Collapse
Affiliation(s)
- Anthony A Lanahan
- From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT
| | - Diana Lech
- From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT
| | - Alexandre Dubrac
- From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT
| | - Jiasheng Zhang
- From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT
| | - Zhen W Zhuang
- From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT
| | - Anne Eichmann
- From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT
| | - Michael Simons
- From the Yale Cardiovascular Research Center, Section of Cardiovascular Medicine, Department of Internal Medicine (A.A.L., D.L., A.D., J.Z., Z.W.Z., A.E., M.S.) and the Department of Cell Biology (M.S.), Yale University School of Medicine, New Haven, CT.
| |
Collapse
|
27
|
Nie L, Guo X, Esmailzadeh L, Zhang J, Asadi A, Collinge M, Li X, Kim JD, Woolls M, Jin SW, Dubrac A, Eichmann A, Simons M, Bender JR, Sadeghi MM. Transmembrane protein ESDN promotes endothelial VEGF signaling and regulates angiogenesis. J Clin Invest 2013; 123:5082-97. [PMID: 24177422 DOI: 10.1172/jci67752] [Citation(s) in RCA: 42] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2012] [Accepted: 08/29/2013] [Indexed: 12/21/2022] Open
Abstract
Aberrant blood vessel formation contributes to a wide variety of pathologies, and factors that regulate angiogenesis are attractive therapeutic targets. Endothelial and smooth muscle cell-derived neuropilin-like protein (ESDN) is a neuropilin-related transmembrane protein expressed in ECs; however, its potential effect on VEGF responses remains undefined. Here, we generated global and EC-specific Esdn knockout mice and demonstrated that ESDN promotes VEGF-induced human and murine EC proliferation and migration. Deletion of Esdn in the mouse interfered with adult and developmental angiogenesis, and knockdown of the Esdn homolog (dcbld2) in zebrafish impaired normal vascular development. Loss of ESDN in ECs blunted VEGF responses in vivo and attenuated VEGF-induced VEGFR-2 signaling without altering VEGF receptor or neuropilin expression. Finally, we found that ESDN associates with VEGFR-2 and regulates its complex formation with negative regulators of VEGF signaling, protein tyrosine phosphatases PTP1B and TC-PTP, and VE-cadherin. These findings establish ESDN as a regulator of VEGF responses in ECs that acts through a mechanism distinct from neuropilins. As such, ESDN may serve as a therapeutic target for angiogenesis regulation.
Collapse
MESH Headings
- Animals
- Antigens, CD/physiology
- Blood Vessels/embryology
- Cadherins/physiology
- Cells, Cultured
- Ear, External/blood supply
- Endothelium, Vascular/physiology
- Hindlimb/blood supply
- Human Umbilical Vein Endothelial Cells/metabolism
- Humans
- Ischemia/physiopathology
- Membrane Proteins/genetics
- Membrane Proteins/physiology
- Mice
- Mice, Inbred C57BL
- Mice, Knockout
- Neovascularization, Physiologic/physiology
- Neuropilins/physiology
- Protein Tyrosine Phosphatase, Non-Receptor Type 1/physiology
- Protein Tyrosine Phosphatase, Non-Receptor Type 2/physiology
- RNA Interference
- RNA, Small Interfering/pharmacology
- Retinal Vessels/growth & development
- Vascular Endothelial Growth Factor A/physiology
- Vascular Endothelial Growth Factor Receptor-2/physiology
- Zebrafish/embryology
- Zebrafish/genetics
- Zebrafish Proteins/physiology
Collapse
|
28
|
Kuo JH, Chen YP, Liu JS, Dubrac A, Quemener C, Prats H, Bikfalvi A, Wu WG, Sue SC. Alternative C-terminal helix orientation alters chemokine function: structure of the anti-angiogenic chemokine, CXCL4L1. J Biol Chem 2013; 288:13522-33. [PMID: 23536183 DOI: 10.1074/jbc.m113.455329] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND CXCL4L1 is a highly potent anti-angiogenic and anti-tumor chemokine, and its structural information is unknown. RESULTS CXCL4L1 x-ray structure is determined, and it reveals a previously unrecognized chemokine structure adopting a novel C-terminal helix conformation. CONCLUSION The alternative helix conformation enhances the anti-angiogenic activity of CXCL4L1 by reducing the glycosaminoglycan binding ability. SIGNIFICANCE Chemokine C-terminal helix orientation is critical in regulating their functions. Chemokines, a subfamily of cytokines, are small, secreted proteins that mediate a variety of biological processes. Various chemokines adopt remarkable conserved tertiary structure comprising an anti-parallel β-sheet core domain followed by a C-terminal helix that packs onto the β-sheet. The conserved structural feature has been considered critical for chemokine function, including binding to cell surface receptor. The recently isolated variant, CXCL4L1, is a homologue of CXCL4 chemokine (or platelet factor 4) with potent anti-angiogenic activity and differed only in three amino acid residues of P58L, K66E, and L67H. In this study we show by x-ray structural determination that CXCL4L1 adopts a previously unrecognized structure at its C terminus. The orientation of the C-terminal helix protrudes into the aqueous space to expose the entire helix. The alternative helix orientation modifies the overall chemokine shape and surface properties. The L67H mutation is mainly responsible for the swing-out effect of the helix, whereas mutations of P58L and K66E only act secondarily. This is the first observation that reports an open conformation of the C-terminal helix in a chemokine. This change leads to a decrease of its glycosaminoglycan binding properties and to an enhancement of its anti-angiogenic and anti-tumor effects. This unique structure is recent in evolution and has allowed CXCL4L1 to gain novel functional properties.
Collapse
Affiliation(s)
- Je-Hung Kuo
- Institute of Bioinformatics and Structural Biology, National Tsing Hua University, Hsinchu 30013, Taiwan
| | | | | | | | | | | | | | | | | |
Collapse
|
29
|
Sorli SC, Colié S, Albinet V, Dubrac A, Touriol C, Guilbaud N, Bedia C, Fabriàs G, Casas J, Ségui B, Levade T, Andrieu-Abadie N. The nonlysosomal β-glucosidase GBA2 promotes endoplasmic reticulum stress and impairs tumorigenicity of human melanoma cells. FASEB J 2012; 27:489-98. [PMID: 23073830 DOI: 10.1096/fj.12-215152] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/02/2023]
Abstract
Glycosphingolipids, which are abundant at the surface of melanoma cells, play crucial roles in tumor progression. We investigated whether a newly described glycosphingolipid hydrolase, encoded by the GBA2 gene, can modulate human melanoma cell growth and death. GBA2 expression was quantified on melanoma cells by RT-qPCR. The antiproliferative effects of GBA2 were assessed in tumor cells expressing inducible GBA2 and in established melanoma xenografts. As a control an inducible catalytically inactive GBA2 mutant was generated. Sphingolipid levels were monitored by mass spectrometry; unfolded protein response (UPR) and apoptosis were assessed by Western blot and flow cytometry analyses, respectively. We report that GBA2 is down-regulated in melanoma; inducible expression of GBA2 affects endogenous sphingolipid metabolism by promoting glucosylceramide degradation (decrease by 78%) and ceramide generation; this is followed by a UPR that causes apoptosis, subsequent decreased anchorage-independent cell growth, and reduced in vivo tumor growth (by 40%); and all these events are abrogated when expressing a catalytically inactive GBA2. This study documents for the first time the antitumor activity of GBA2 and provides evidence for the role of nonlysosomal glucosylceramide breakdown as a source of bioactive ceramide and a mechanistic link between glycolipid catabolism and the UPR/death response of melanoma cells.
Collapse
Affiliation(s)
- Sonia-Caroline Sorli
- Institut National de Santé et de Recherche Médicale (INSERM) Unité Mixte de Recherche 1037, Centre de Recherches en Cancérologie de Toulouse, Toulouse, France
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
30
|
Genet G, Guilbeau-Frugier C, Honton B, Dague E, Schneider MD, Coatrieux C, Calise D, Cardin C, Nieto C, Payré B, Dubroca C, Marck P, Heymes C, Dubrac A, Arvanitis D, Despas F, Altié MF, Seguelas MH, Delisle MB, Davy A, Sénard JM, Pathak A, Galés C. Ephrin-B1 Is a Novel Specific Component of the Lateral Membrane of the Cardiomyocyte and Is Essential for the Stability of Cardiac Tissue Architecture Cohesion. Circ Res 2012; 110:688-700. [DOI: 10.1161/circresaha.111.262451] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Rationale:
Cardiac tissue cohesion relying on highly ordered cardiomyocytes (CM) interactions is critical because most cardiomyopathies are associated with tissue remodeling and architecture alterations.
Objective:
Eph/ephrin system constitutes a ubiquitous system coordinating cellular communications which recently emerged as a major regulator in adult organs. We examined if eph/ephrin could participate in cardiac tissue cyto-organization.
Methods and Results:
We reported the expression of cardiac ephrin-B1 in both endothelial cells and for the first time in CMs where ephrin-B1 localized specifically at the lateral membrane. Ephrin-B1 knock-out (KO) mice progressively developed cardiac tissue disorganization with loss of adult CM rod-shape and sarcomeric and intercalated disk structural disorganization confirmed in CM-specific ephrin-B1 KO mice. CMs lateral membrane exhibited abnormal structure by electron microscopy and notably increased stiffness by atomic force microscopy. In wild-type CMs, ephrin-B1 interacted with claudin-5/ZO-1 complex at the lateral membrane, whereas the complex disappeared in KO/CM-specific ephrin-B1 KO mice. Ephrin-B1 deficiency resulted in decreased mRNA expression of CM basement membrane components and disorganized fibrillar collagen matrix, independently of classical integrin/dystroglycan system. KO/CM-specific ephrin-B1 KO mice exhibited increased left ventricle diameter and delayed atrioventricular conduction. Under pressure overload stress, KO mice were prone to death and exhibited striking tissue disorganization. Finally, failing CMs displayed downregulated ephrin-B1/claudin-5 gene expression linearly related to the ejection fraction.
Conclusions:
Ephrin-B1 is necessary for cardiac tissue architecture cohesion by stabilizing the adult CM morphology through regulation of its lateral membrane. Because decreased ephrin-B1 is associated with molecular/functional cardiac defects, it could represent a new actor in the transition toward heart failure.
Collapse
Affiliation(s)
- Gaël Genet
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Céline Guilbeau-Frugier
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Benjamin Honton
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Etienne Dague
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Michael D. Schneider
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Christelle Coatrieux
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Denis Calise
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Christelle Cardin
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Cécile Nieto
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Bruno Payré
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Caroline Dubroca
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Pauline Marck
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Christophe Heymes
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Alexandre Dubrac
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Dina Arvanitis
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Fabien Despas
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Marie-Françoise Altié
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Marie-Hélène Seguelas
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Marie-Bernadette Delisle
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Alice Davy
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Jean-Michel Sénard
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Atul Pathak
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| | - Céline Galés
- From the Institut des Maladies Métaboliques et Cardiovasculaires, Institut National de la Santé et de la Recherche Médicale UMR 1048 (G.G., B.H., C.C., F.D., M.F.A., M.H.S., J.M.S., A.P., C.G., A.D., D.C., C.D., P.M., C.H.), Department of Histopathology (C.G.F., M.B.D.) and of Clinical Pharmacology (F.D., J.M.S., A.P.), Toulouse University Hospital, CNRS; LAAS, ITAV-UMS3039 (E.D.), Centre de Microscopie Électronique Appliquée à la Biologie, Rangueil Medical Faculty (C.N., B.P.), Development biology
| |
Collapse
|